Regeneron Pharmaceuticals D
D
REGN
616.68
USD
-17.36
(-2.74%)
مغلق
حجم التداول
33,339
الربح لكل سهم
45
العائد الربحي
0.14
P/E
16
حجم السوق
67,418,344,896
الأخبار المقالات
العنوان: Regeneron Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).